Imunon Inc (IMNN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.08M
Last updated: Nov 17, 2026 at 11:04 AM ET
Imunon Inc (IMNN) Earnings: Report Dates and Results
Imunon (IMNN) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Imunon reported EPS of -$0.64, in line with the -$0.64 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IMNN has an expected report date of Mar 29, 2027.
IMNN Earnings Call
The latest IMNN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, IMNN beat 20, missed 17 and matched 2. The widest gap in the table came in the quarter ended Dec 31, 2021, when EPS landed 302.22% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.64 | -$0.64 | -$0.71 - -$0.45 | 0.00% | In line | N/A | 4 | N/A | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.54 | -$0.94 | N/A | +42.55% | Beat | N/A | 4 | 0 up, 0 down | Aug 11, 2026 | N/A |
| Mar 31, 2026 | -$0.84 | -$1.28 | -$1.30 - -$1.25 | +34.38% | Beat | N/A | 3 | 0 up, 0 down | May 12, 2026 | N/A |
| Dec 31, 2025 | -$1.30 | -$1.82 | -$3.45 - -$1.22 | +28.57% | Beat | N/A | 4 | 1 up, 0 down | Mar 31, 2026 | N/A |
| Sep 30, 2025 | -$1.16 | -$1.82 | -$1.95 - -$1.70 | +36.26% | Beat | N/A | 2 | 1 up, 0 down | Nov 13, 2025 | N/A |
| Jun 30, 2025 | -$1.87 | -$4.34 | -$8.40 - -$3.45 | +56.91% | Beat | N/A | 4 | 2 up, 0 down | Aug 5, 2025 | N/A |
| Mar 31, 2025 | -$3.65 | -$4.66 | -$6.45 - -$4.20 | +21.67% | Beat | N/A | 4 | 0 up, 0 down | May 12, 2025 | N/A |
| Dec 31, 2024 | -$0.25 | -$0.36 | -$0.40 - -$0.32 | +30.56% | Beat | N/A | 2 | 0 up, 0 down | Feb 27, 2025 | $727160 |
| Sep 30, 2024 | -$4.43 | -$5.35 | -$7.35 - -$4.65 | +17.20% | Beat | N/A | 4 | 0 up, 0 down | Nov 7, 2024 | N/A |
| Jun 30, 2024 | -$6.65 | -$6.65 | N/A | 0.00% | In line | N/A | 3 | 0 up, 0 down | Aug 14, 2024 | N/A |
| Mar 31, 2024 | -$6.78 | -$7.39 | -$10.19 - -$7.20 | +8.25% | Beat | N/A | 3 | 0 up, 0 down | May 13, 2024 | N/A |
| Dec 31, 2023 | -$0.52 | -$0.41 | -$0.41 - -$0.41 | -26.83% | Miss | N/A | 1 | 0 up, 0 down | Mar 28, 2024 | $7.05M |
| Sep 30, 2023 | -$4.83 | -$7.30 | N/A | +33.84% | Beat | N/A | 3 | 0 up, 0 down | Nov 14, 2023 | N/A |
| Jun 30, 2023 | -$7.46 | -$7.70 | N/A | +3.12% | Beat | N/A | 2 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$8.87 | -$8.09 | N/A | -9.64% | Miss | N/A | 3 | 0 up, 0 down | May 11, 2023 | N/A |
| Dec 31, 2022 | -$1.61 | -$0.85 | -$0.90 - -$0.79 | -89.41% | Miss | N/A | 3 | 0 up, 0 down | Mar 30, 2023 | $125000 |
| Sep 30, 2022 | -$11.35 | -$10.30 | N/A | -10.19% | Miss | N/A | 3 | 0 up, 0 down | Nov 14, 2022 | $125000 |
| Jun 30, 2022 | -$11.35 | -$11.80 | N/A | +3.81% | Beat | N/A | N/A | N/A | Aug 15, 2022 | $125000 |
| Mar 31, 2022 | -$23.74 | -$13.30 | N/A | -78.50% | Miss | N/A | N/A | N/A | May 16, 2022 | $125000 |
| Dec 31, 2021 | -$3.62 | -$0.90 | N/A | -302.22% | Miss | N/A | N/A | N/A | Mar 31, 2022 | $125000 |
| Sep 30, 2021 | -$11.74 | -$16.63 | N/A | +29.40% | Beat | N/A | N/A | N/A | Nov 15, 2021 | $125000 |
| Jun 30, 2021 | -$0.90 | -$1.20 | N/A | +25.00% | Beat | N/A | N/A | N/A | Aug 12, 2021 | $125000 |
| Mar 31, 2021 | -$1.35 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2021 | $125000 |
| Dec 31, 2020 | -$9.78 | -$25.43 | N/A | +61.54% | Beat | N/A | N/A | N/A | Mar 19, 2021 | $125000 |
| Sep 30, 2020 | -$46.96 | -$25.43 | N/A | -84.66% | Miss | N/A | N/A | N/A | Nov 16, 2020 | $125000 |
| Jun 30, 2020 | -$35.22 | -$29.35 | N/A | -20.00% | Miss | N/A | N/A | N/A | Aug 14, 2020 | $125000 |
| Mar 31, 2020 | -$3.00 | -$2.55 | N/A | -17.65% | Miss | N/A | N/A | N/A | May 15, 2020 | $125000 |
| Dec 31, 2019 | -$19.57 | -$39.13 | N/A | +49.99% | Beat | N/A | N/A | N/A | Mar 25, 2020 | $125000 |
| Sep 30, 2019 | -$48.91 | -$52.83 | N/A | +7.42% | Beat | N/A | N/A | N/A | Nov 14, 2019 | $125000 |
| Jun 30, 2019 | -$56.74 | -$64.57 | N/A | +12.13% | Beat | N/A | N/A | N/A | Aug 14, 2019 | $125000 |
| Mar 31, 2019 | -$23.48 | -$48.91 | N/A | +51.99% | Beat | N/A | N/A | N/A | May 15, 2019 | $125000 |
| Dec 31, 2018 | -$4.20 | -$2.05 | N/A | -104.88% | Miss | N/A | N/A | N/A | Mar 29, 2019 | $125000 |
| Sep 30, 2018 | -$50.87 | -$43.04 | N/A | -18.19% | Miss | N/A | N/A | N/A | Nov 14, 2018 | $125000 |
| Jun 30, 2018 | -$90.00 | -$52.83 | N/A | -70.36% | Miss | N/A | N/A | N/A | Aug 14, 2018 | $125000 |
| Mar 31, 2018 | -$48.91 | -$58.70 | N/A | +16.68% | Beat | N/A | N/A | N/A | May 11, 2018 | $125000 |
| Dec 31, 2017 | -$4.68 | -$4.57 | N/A | -2.41% | Miss | N/A | N/A | N/A | Mar 27, 2018 | $125000 |
| Sep 30, 2017 | -$136.96 | -$109.57 | N/A | -25.00% | Miss | N/A | N/A | N/A | Nov 14, 2017 | $125000 |
| Jun 30, 2017 | -$154.57 | -$74.35 | N/A | -107.90% | Miss | N/A | N/A | N/A | Aug 14, 2017 | $125000 |
| Mar 31, 2017 | -$328.70 | -$301.31 | N/A | -9.09% | Miss | N/A | N/A | N/A | May 12, 2017 | $125000 |
| Dec 31, 2016 | -$39.90 | -$38.85 | N/A | -2.70% | Miss | N/A | N/A | N/A | Mar 16, 2017 | $125000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$7.98, after -$18.11 the year before. It was -$1,847.74 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$7.98 | N/A |
| Dec 31, 2024 | -$18.11 | N/A |
| Dec 31, 2023 | -$21.68 | N/A |
| Dec 31, 2022 | -$48.05 | N/A |
| Dec 31, 2021 | -$17.61 | N/A |
| Dec 31, 2020 | -$94.96 | N/A |
| Dec 31, 2019 | -$148.70 | N/A |
| Dec 31, 2018 | -$193.98 | N/A |
| Dec 31, 2017 | -$624.91 | N/A |
| Dec 31, 2016 | -$1,847.74 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,100 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,114 | 7 | |
| 2026Q2 | Jun 30, 2026 | 4,897 | 9 | |
| 2026Q1 | Mar 31, 2026 | 3,975 | 9 | |
| 2025Q4 | Dec 31, 2025 | 4,459 | 10 | |
| 2025Q3 | Sep 30, 2025 | 6,428 | 9 | |
| 2025Q2 | Jun 30, 2025 | 5,002 | 10 | |
| 2025Q1 | Mar 31, 2025 | 3,065 | 7 | |
| 2024Q4 | Dec 31, 2024 | 7,581 | 11 |
2026Q3 Earnings Call
Opening remarks
Valter Pinto Managing Director, KCSA Strategic Communications Thank you, operator, and good morning. Welcome to the Imunon third quarter 2026 financial results and business update conference call. Joining us today are Dr. Stacy Lindborg, President and Chief Executive Officer; Dr. Douglas Faller, Executive Vice President and Chief Medical Officer; and Josh Blacher, Interim Chief Financial Officer. Michael Tardugno, Executive Chairman, is also available for the question-and-answer portion of today's call. Before we begin, I'd like to remind everyone that our remarks today include forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include, but are not limited to, statements regarding the timing and enrollment of the company's clinical trials, the potential of the company's therapies to address unmet medical needs, the market potential for its product candidates, if approved, and the company's plans and expectations for its development programs. Words such as may, will, expect, plan, anticipate, estimate, and intend identify these forward-looking statements. Actual results may differ materially from those projected. Additional information on the factors that could cause actual results to differ is detailed in Imunon's filings with the Securities and Exchange Commission, which are available at sec.gov and on the company's website. The forward-looking statements made on this call speak only as of today's date, and the company undertakes no obligation to update them, except as required by law. With that, I'd now like to turn the call over to Dr. Stacy Lindborg, President and Chief Executive Officer. Stacy?
Stacy Lindborg President and Chief Executive Officer Thank you, Valter, and good morning, everyone. Thank you for joining us today and for your continued support of Imunon. On our second quarter call in August, I said our priorities were clear: execute our Phase III OVATION-3 study, generate high-quality data, and deliver a much-needed therapy option for women with advanced ovarian cancer. The third quarter was a period in which we advanced all three, continued OVATION-3 enrollment, generated additional external validation of the data, and took further portfolio and capital structure actions. We recently hosted our 2026 R&D Day in New York City, where clinical investigators presented the full case for the Phase III IMNN-001 study in frontline ovarian cancer, which included the final Phase II overall survival results, the preliminary minimal residual disease findings, and the path to a confirmatory readout in OVATION-3. Our North Star remains unchanged: bringing a much-needed treatment option to women with advanced ovarian cancer, a disease that affects approximately 300,000 women worldwide each year, has five-year survival rates of approximately 41% for women diagnosed at Stage III and approximately 20% for women diagnosed at Stage IV, and has seen little advancement in frontline care, the standard of care for well over two decades.
Frequently Asked Questions About IMNN
When is Imunon's next earnings date?
Imunon's next earnings report is expected for Mar 29, 2027.
Did IMNN beat earnings estimates last quarter?
Imunon reported EPS of -$0.64 for the quarter ended Sep 30, 2026, in line with the -$0.64 estimate.
What EPS do analysts expect from IMNN next quarter?
The consensus EPS estimate for Imunon for the quarter ending Dec 31, 2026 is -$0.51 from 7 analysts, with estimates from -$0.72 to -$0.25.
How often does IMNN beat earnings estimates?
Imunon beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +31.36%.
IMNN pages: Overview, Earnings, Forecast, Financials, Competitors